BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19500979)

  • 1. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
    Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4268-73. PubMed ID: 19500979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
    Kasai S; Kamata M; Masada S; Kunitomo J; Kamaura M; Okawa T; Takami K; Ogino H; Nakano Y; Ashina S; Watanabe K; Kaisho T; Imai YN; Ryu S; Nakayama M; Nagisa Y; Takekawa S; Kato K; Murata T; Suzuki N; Ishihara Y
    J Med Chem; 2012 May; 55(9):4336-51. PubMed ID: 22490048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities.
    Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Discov Technol; 2012 Mar; 9(1):25-38. PubMed ID: 22235926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1).
    Lim CJ; Kim SH; Lee BH; Oh KS; Yi KY
    Bioorg Med Chem Lett; 2012 Jan; 22(1):427-30. PubMed ID: 22137790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
    Surman MD; Freeman EE; Grabowski JF; Hadden M; Henderson AJ; Jiang G; Jiang XM; Luche M; Khmelnitsky Y; Vickers S; Viggers J; Cheetham S; Guzzo PR
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7015-9. PubMed ID: 20961756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
    Roth GJ; Heckel A; Kley JT; Lehmann T; Müller SG; Oost T; Rudolf K; Arndt K; Budzinski R; Lenter M; Lotz RR; Schindler M; Thomas L; Stenkamp D
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3270-4. PubMed ID: 26077492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).
    Rowbottom MW; Vickers TD; Tamiya J; Zhang M; Dyck B; Grey J; Schwarz D; Heise CE; Hedrick M; Wen J; Tang H; Wang H; Fisher A; Aparicio A; Saunders J; Goodfellow VS
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2171-8. PubMed ID: 17350839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists.
    Lim CJ; Kim JY; Lee BH; Oh KS; Yi KY
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1736-9. PubMed ID: 23411080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.
    Kasai S; Kamaura M; Kamata M; Aso K; Ogino H; Nakano Y; Watanabe K; Kaisho T; Tawada M; Nagisa Y; Takekawa S; Kato K; Suzuki N; Ishihara Y
    Bioorg Med Chem; 2011 Nov; 19(21):6261-73. PubMed ID: 21975069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.
    Judd AS; Souers AJ; Kym PR
    Curr Top Med Chem; 2008; 8(13):1152-7. PubMed ID: 18782010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity.
    Galiano S; Ceras J; Cirauqui N; Pérez S; Juanenea L; Rivera G; Aldana I; Monge A
    Bioorg Med Chem; 2007 Jun; 15(11):3896-911. PubMed ID: 17407817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
    Mihalic JT; Fan P; Chen X; Chen X; Fu Y; Motani A; Liang L; Lindstrom M; Tang L; Chen JL; Jaen J; Dai K; Li L
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3781-5. PubMed ID: 22542010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
    Souers AJ; Gao J; Brune M; Bush E; Wodka D; Vasudevan A; Judd AS; Mulhern M; Brodjian S; Dayton B; Shapiro R; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
    J Med Chem; 2005 Mar; 48(5):1318-21. PubMed ID: 15743174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New amide derivatives as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
    Cirauqui N; Ceras J; Galiano S; Pérez-Silanes S; Juanenea L; Rivera G; Aldana I; Monge A
    Arzneimittelforschung; 2008; 58(11):585-91. PubMed ID: 19137910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
    Judd AS; Souers AJ; Wodka D; Zhao G; Mulhern MM; Iyengar RR; Gao J; Lynch JK; Freeman JC; Falls HD; Brodjian S; Dayton BD; Reilly RM; Gintant G; Limberis JT; Mikhail A; Leitza ST; Houseman KA; Diaz G; Bush EN; Shapiro R; Knourek-Segel V; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2365-71. PubMed ID: 17350253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2.
    Chen X; Mihalic J; Fan P; Liang L; Lindstrom M; Wong S; Ye Q; Fu Y; Jaen J; Chen JL; Dai K; Li L
    Bioorg Med Chem Lett; 2012 Jan; 22(1):363-6. PubMed ID: 22123324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
    Högberg T; Frimurer TM; Sasmal PK
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6039-47. PubMed ID: 22954736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas.
    McBriar MD; Guzik H; Shapiro S; Paruchova J; Xu R; Palani A; Clader JW; Cox K; Greenlee WJ; Hawes BE; Kowalski TJ; O'neill K; Spar BD; Weig B; Weston DJ; Farley C; Cook J
    J Med Chem; 2006 Apr; 49(7):2294-310. PubMed ID: 16570926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.